Advanced Cell Diagnostics is a technology company.
Advanced Cell Diagnostics has raised $34.0M across 2 funding rounds.
Advanced Cell Diagnostics has raised $34.0M in total across 2 funding rounds.
Advanced Cell Diagnostics has raised $34.0M in total across 2 funding rounds.
Advanced Cell Diagnostics's investors include Samsara BioCapital.
Advanced Cell Diagnostics (ACD) is a biotechnology company specializing in molecular pathology tools for personalized medicine, now operating as a brand under Bio-Techne. It develops the proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization (ISH) platform that detects and quantifies RNA biomarkers in intact cells and tissues at single-molecule sensitivity, enabling precise spatial gene expression analysis.[1][2][3] ACD serves researchers, pharmaceutical companies, and diagnostic labs by providing assay kits, target probes (over 15,000 off-the-shelf options), custom probe design, professional assay services, and automated solutions compatible with systems from Leica Biosystems and Roche.[2][4][5] This addresses key challenges in biomarker validation for cancer management and targeted therapies, shortening development timelines to weeks while overcoming issues like patient heterogeneity and background noise in traditional RNA detection.[1][3]
The company's growth momentum reflects its integration into Bio-Techne, expanding its reach through partnerships and a global network, with products like RNAscope, BaseScope, miRNAscope, and DNAscope fueling adoption in discovery, preclinical, and clinical studies.[2][4][7]
ACD was founded in the heart of Silicon Valley by experienced life science entrepreneurs, though specific founder names are not detailed in available records.[1][3] The idea emerged from the need to advance RNA in situ hybridization (ISH) beyond limitations of sensitivity and specificity, leading to the creation of RNAscope®—a breakthrough probe design that amplifies target signals while suppressing noise.[1][3][8] Early traction came from positioning RNAscope as a tool for biomarker identification in personalized medicine, particularly for companion diagnostics in cancer, with partnerships forming alongside internal diagnostic test development.[1] A pivotal evolution occurred through acquisition by Bio-Techne, transforming ACD into a brand that leverages the parent's resources for broader commercialization and innovation in spatial biology.[2][5][6]
ACD rides the wave of spatial biology and transcriptomics, where understanding gene expression in tissue context is critical for precision oncology, immunotherapy, and next-generation therapeutics.[2][8] Timing aligns with surging demand for multiplex ISH amid advances in single-cell analysis and AI-driven pathology, as RNA biomarkers prove essential for stratifying heterogeneous diseases like cancer.[1][3] Market forces favoring ACD include pharma's push for companion diagnostics, regulatory emphasis on personalized medicine, and automation trends in labs, amplified by Bio-Techne's distribution network and partnerships with Leica and Roche.[5][6] It influences the ecosystem by setting the gold standard for in situ RNA detection, enabling breakthroughs like stem cell niche mapping and pathway analysis, thus accelerating drug discovery and diagnostics.[2][8]
ACD's trajectory points toward deeper integration of RNAscope® in clinical workflows, with expansions in automation, custom probes, and multi-omics (e.g., combining RNA with protein via TSA Vivid kits).[2][3][4] Trends like AI-enhanced image analysis and rising ASO/siRNA therapies will amplify demand for its miRNAscope and high-plex capabilities.[4][8] As spatial multiomics matures, ACD could evolve influence by powering routine companion diagnostics, potentially capturing share in a market projected to grow with precision medicine adoption—building on its Silicon Valley roots to unlock RNA's full diagnostic power.[1][2]
Advanced Cell Diagnostics has raised $34.0M across 2 funding rounds. Most recently, it raised $22.0M Series C in June 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2015 | $22.0M Series C | Samsara BioCapital | |
| Oct 1, 2012 | $12.0M Series B | Samsara BioCapital |